Design, synthesis, and antitumor evaluation of new functionalized spiroindenopyridotriazinepyrans

Cancer is the second leading cause of death worldwide. Main problem in current cancer therapy strategies is resistance to anti-cancer drugs and side effects. Therefore, the design of new compounds with high anticancer activity and low toxicity toward normal cells is highly desirable. In the present study, we focused on the development of novel spiropyran derivatives. A practical one-pot synthetic method was developed for preparation of spiroindenopyridotriazinepyrans containing pyranopyridine, and triazine constituent units within a unified molecular framework. This method employs readily accessible starting materials, proceeds under mild conditions, and affords products that can be purified without chromatographic techniques. The structures of the products were confirmed by NMR, IR, and mass spectrometry. Moreover, we explored the anticancer effects of related products against human pancreatic cancer cells (Panc1), human breast cancer cells (MDA-MB-231) and normal cells HDF (human dermal fibroblast) by using MTT assay and DAPI staining. Our results revealed that 9d, 9e, and 9f compounds have the highest cytotoxic activity on different cancer cells. It seems that these synthetic compounds may be a promising candidate to design therapeutic agents against different cancers.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-02-09
DOI
https://doi.org/10.1038/s41598-026-38946-1
Primary Topic
Photochromic and Fluorescence Chemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design, synthesis, and antitumor evaluation of new functionalized spiroindenopyridotriazinepyrans

Fatemeh Safari, Atefeh Homaee, Hajar Hosseini, Mohammad Bayat
Scientific Reports
Photochromic and Fluorescence Chemistry
article

Design, synthesis, and antitumor evaluation of new functionalized spiroindenopyridotriazinepyrans

Fatemeh Safari, Atefeh Homaee, Hajar Hosseini, Mohammad Bayat
article en

Abstract

Cancer is the second leading cause of death worldwide. Main problem in current cancer therapy strategies is resistance to anti-cancer drugs and side effects. Therefore, the design of new compounds with high anticancer activity and low toxicity toward normal cells is highly desirable. In the present study, we focused on the development of novel spiropyran derivatives. A practical one-pot synthetic method was developed for preparation of spiroindenopyridotriazinepyrans containing pyranopyridine, and triazine constituent units within a unified molecular framework. This method employs readily accessible starting materials, proceeds under mild conditions, and affords products that can be purified without chromatographic techniques. The structures of the products were confirmed by NMR, IR, and mass spectrometry. Moreover, we explored the anticancer effects of related products against human pancreatic cancer cells (Panc1), human breast cancer cells (MDA-MB-231) and normal cells HDF (human dermal fibroblast) by using MTT assay and DAPI staining. Our results revealed that 9d, 9e, and 9f compounds have the highest cytotoxic activity on different cancer cells. It seems that these synthetic compounds may be a promising candidate to design therapeutic agents against different cancers.

Scientific ReportsVol. 16(1)
Imam Khomeini International University (IR), University of Guilan (IR)
Good health and well-being
Openalex Percentile: Top 63%
Photochromic and Fluorescence Chemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.